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ABSTRACT
Background/Objectives: This study will aim to
characterise disease behaviour during the peri-
diagnostic period in patients with suspected
interstitial lung disease (ILD), including
idiopathic pulmonary fibrosis (IPF), using daily
home spirometry and accelerometry. Addition-
ally, this study will aim to increase collabora-
tion between secondary and tertiary centres
using a digital collaboration platform.
Methods: The STARLINER study (NCT03261037)
will enrol approximately 180 symptomatic
patients aged 50 years or more with radiological
evidence of ILD/IPF from community and ter-
tiary centres in Canada and Europe. Approxi-
mately two-thirds of sites will be community
centres. Patients will be followed during pre-
diagnosis (inclusion to diagnosis; up to a max-
imum of 12 months) and post-diagnosis (diag-
nosis to treatment initiation; up to a maximum
of 6 months). The study will be facilitated by a
digital ecosystem consisting of the devices used
for home-based assessments and a digital col-
laboration platform enabling communication
between community and tertiary centres, and
between clinicians and patients.
Planned Outcomes: The primary endpoint will
be time-adjusted semi-annual change in forced
vital capacity (FVC; in millilitres) during the
peri-diagnostic period. Physical functional
capacity and patient-reported outcomes (PROs)
will also be assessed. FVC and physical func-
tional capacity will be measured using daily
home spirometry and accelerometry, and at site
visits using spirometry and the 6-min walk test.
PROs will be assessed prior to, or during, site
visits and will always be completed in the same
order.
Enhanced Digital Features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.7358393.
Electronic supplementary material The online
version of this article (https://doi.org/10.1007/s12325-
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Conclusions: Findings from this study may
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disease progression, enabling collaboration
between community and tertiary centres and
improving communication between clinicians
and patients.
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PLAIN LANGUAGE SUMMARY
Interstitial lung diseases (ILDs) are a group of
disorders involving inflammation and/or scar-
ring of the lungs. The cause of ILD can be unclear
in some patients. Diagnosis of ILD can be com-
plicated, and patients sometimes have to wait
more than 12 months before being diagnosed.
Reasons why patients might wait a long time
for a diagnosis include:
• The symptoms of ILD can be confused with
those of other conditions. Therefore,
patients with ILD are sometimes told they
have another disease first.
• Patients with ILD are usually treated at
specialist hospitals by doctors who are
experts in ILD. Some patients have to wait
a long time for an appointment at these
specialist centres and have to travel long
distances to their nearest centre.
If doctors could learn more about ILD from
clinical studies and how symptoms change over
time, they might be able to diagnose ILD faster.
This paper describes the STARLINER study,
which will include patients whose doctors think
they might have an ILD. An online system will
be used to track measurements that patients
take at home, and will allow communication
between community and specialist centres and
between doctors and patients. STARLINER will
assess changes in how well patients’ lungs work,
which patients will measure at home. Patients
will also provide their daily step count and
calorie use by wearing a smartwatch. It is hoped
that the findings from this study will increase
understanding of how ILD develops, leading to
earlier diagnosis and improving communica-
tion between doctors and patients.
INTRODUCTION
The interstitial lung diseases (ILDs) are a diverse
group of disorders characterised by inflamma-
tion and/or fibrosis of the lungs [1, 2]. Although
some patients may have a known or suspected
cause of ILD, such as an underlying connective
tissue disease or certain environmental or
occupational exposures, other patients may lack
a clear cause [1, 2]. Idiopathic pulmonary
fibrosis (IPF), which is a progressive and fatal
disease of unclear aetiology, is among the most
common of the ILDs [3, 4]. IPF is generally more
prevalent in men and current or ex-smokers,
and is primarily diagnosed in the sixth or sev-
enth decade of life [4–6]. There are currently no
available treatments for IPF that can reverse
lung damage; however, two antifibrotics, pir-
fenidone and nintedanib, have been shown to
significantly reduce disease progression in
patients with IPF vs. placebo [7–10]. With the
availability of therapies that can slow disease
progression, earlier diagnosis and treatment of
IPF may potentially lead to improved patient
outcomes, particularly if patients can be diag-
nosed before substantial irreversible lung dam-
age has occurred [11, 12].
The diagnosis of ILDs, including IPF, is a
complex process, and many patients experience
delays of over 12 months [13–15]. Misdiagnosis
is a key cause of delays, with evidence suggest-
ing that 55% of patients experience at least one
misdiagnosis prior to a diagnosis of ILD [13].
Factors leading to misdiagnosis include the
non-specific nature of initial symptoms in ILD
[13] and geographical barriers to accessing spe-
cialist centres and multidisciplinary teams
(MDTs) [16]. Delayed access to specialist centres
is associated with an increased risk of mortality
independent of pulmonary function [14] and
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may lead to the use of inappropriate or inef-
fective treatments. In addition, previous studies
have shown that input from an MDT can lead to
more accurate and confident diagnosis of ILD
[17, 18]. Therefore, there is a need for increased
collaboration between secondary and tertiary
centres to increase access to MDTs and subse-
quently improve the diagnosis of ILDs, with
virtual MDTs holding some promise, particu-
larly for the diagnosis of IPF [19].
An additional barrier to the early diagnosis
and treatment of ILD is the current lack of evi-
dence characterising ILD behaviour and pro-
gression during the early stages of disease [20].
In general, clinical trials investigating patients
with ILD have collected data after diagnosis
and initiation of treatment, with clinical
measurements performed approximately every
3–6 months [8, 9, 21]. As such, there is a clear
need for study designs utilising more frequent
data collection, with a focus on defining disease
trajectories during the pre- and post-diagnostic
periods (peri-diagnostic period) in patients with
ILD. Observational studies utilising daily home
spirometry and accelerometry have shown that
these measurements by patients with IPF are
feasible to perform [22–26], and can be used to
predict mortality [23, 26]. In combination with
the benefit of allowing daily measurements,
these observations suggest that home-based
assessments could be utilised for the character-
isation of early disease behaviour in ILDs,
potentially guiding diagnostic decisions [27].
This paper describes the design of a study
aiming to characterise disease behaviour in
patients with ILD, including IPF, during the
peri-diagnostic period using daily home-based
measurements. Communication between com-
munity and ILD tertiary centres will be facili-
tated by a digital collaboration platform.
METHODS
Study Design
The STARLINER study (ClinicalTrials.gov
NCT03261037) is a multicentre, ongoing study
that plans to enrol approximately 180 patients
across approximately 40 community and
tertiary clinical centres in Canada, France, Ire-
land, Italy, the Netherlands and Russia (for
further details, visit https://clinicaltrials.gov/
ct2/show/study/NCT03261037). To reflect clin-
ical practice, where many patients may not be
treated at ILD tertiary centres (i.e. specialist
centres), this study will aim for approximately
two-thirds of sites to be community centres.
This study will assess disease behaviour in
patients with suspected ILD, including IPF,
during the peri-diagnostic period, which will
consist of the pre-diagnostic period (from
inclusion to diagnosis; up to a maximum of
12 months) and the post-diagnostic period
(from diagnosis to treatment initiation; or up to
6 months after diagnosis) (Fig. 1). Disease
behaviour will be assessed in terms of pul-
monary function and physical functional
capacity, which will be measured at home using
daily spirometry and accelerometry, respec-
tively, and at site visits using site spirometry
and the 6-min walk test (6MWT), respectively.
Patients will leave the study if they do not
receive a diagnosis within 12 months of inclu-
sion or if they receive a non-ILD diagnosis
(Fig. 1). Patients diagnosed with ILD within
12 months of inclusion will remain in the study
for a maximum of 6 months after the patient
receives a diagnosis from the investigator, or
until the date treatment commences. Therefore,
the total length of the study will vary for each
patient (up to a maximum of 18 months)
depending on their individual patient journey
and local clinical practice.
The study design will be facilitated by a
digital ecosystem consisting of two pillars
(Fig. 2). Pillar 1 will comprise the spirometers
and accelerometers that will be used for home-
based assessments, which will have a real-time
connection to a tablet computer, allowing
patients to view their results in real time. Pillar 2
will include the digital collaboration platform,
which will enable virtual MDT discussions
between community and tertiary sites (Fig. 2).
Additionally, the tablet computer will act as a
bridge between the two pillars, linking the
patient data to the collaboration platform,
where investigators will be able to access their
patients’ data in real time (Fig. 2).
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Fig. 1 Study procedures. ILD interstitial lung disease, IPF idiopathic pulmonary ﬁbrosis. aPatients will leave the study if
there is no diagnosis within 12 months of inclusion or a non-ILD diagnosis
Fig. 2 Digital ecosystem. FVC forced vital capacity, ILD interstitial lung disease, IPF idiopathic pulmonary ﬁbrosis,
MDT multidisciplinary team
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Sample Selection
Symptomatic patients (unexplained dyspnoea
on exertion and/or cough) with suspected ILD/
IPF aged 50 years or more with radiological
evidence (on chest radiograph or computed
tomography scan) of ILD/IPF will be eligible for
inclusion. In accordance with the investigators’
judgement, patients must be able to comply
with the study protocol and must provide
signed informed consent to the investigators.
Patients will be excluded if they participate in
any investigational study within 28 days prior
to inclusion, have a history of clinically signif-
icant cardiac disease that could explain their
symptomatology in the opinion of the investi-
gators, or have a known history of any con-
nective tissue disease, including, but not limited
to, rheumatoid arthritis, scleroderma, systemic
lupus erythematosus or mixed connective tissue
disease.
Measurements
No investigational medicinal product will be
assessed in this study, and patients will be man-
aged according to the standard of care at the
discretion of the treating clinician. All medica-
tions taken for comorbid conditions will be
continued as necessary and will be recorded
throughout the study. Three mandatory site
visits will be conducted at baseline, diagnosis
and end of study for each individual patient, and
additional site visits will be scheduled at the
discretion of the investigator. This study will be
conducted under real-life conditions, and
therefore the timing of all mandatory and addi-
tional site visits will not be pre-determined,
although additional site visits should include at
least one visit during each study period (pre- and
post-diagnosis). Mandatory assessments will
consist of pulmonary function, physical func-
tional capacity and patient-reported outcome
(PRO) measures (see Table S1 in the Electronic
SupplementaryMaterial). Any other assessments
will be performed at the discretion of investiga-
tors, according to local clinical practice.
For home-based assessments, daily measure-
ment of forced vital capacity (FVC; in
millilitres) will be performed using a
portable handheld spirometer (Spirobank
Smart; Medical International Research, Rome,
Italy) (Table 1). Patients will receive training on
how to perform spirometry at enrolment and
will perform ‘‘test blows’’ until they can
demonstrate a reliable manoeuvre. Patients will
also be provided with a manual and will have
access to a digital avatar to help them complete
the spirometry assessments successfully. Physi-
cal functional capacity will be assessed using
continuous daily measurement of steps per day
and calorie expenditure with an accelerometer
resembling a watch (Steel HR; Withings, Issy-
les-Moulineaux, France) (Table 1), which will be
worn around the wrist. Patients will receive
training on how to use the accelerometer at
enrolment and will be provided with an
instruction manual for the device.
At site visits, pulmonary function and phys-
ical functional capacity will be assessed,
according to the instructions provided to
investigators in the study procedure manual,
using site spirometry and the 6MWT, respec-
tively (Table 1; see also Table S1 in the Electronic
Supplementary Material). The 6MWT will only
be performed at sites where a formalised process
is available and the test can be performed under
safe conditions. Patients will complete the PRO
assessments at baseline and at the request of the
investigator just prior to, or during, site visits,
and they will always be completed in the same
order. PROs will include the King’s Brief Inter-
stitial Lung Disease questionnaire, the modified
Medical Research Council Dyspnoea Scale, the
5-Level EuroQol 5-Dimension questionnaire,
the Fatigue Assessment Scale, a Cough-Visual
Analogue Scale (VAS), an Urge-to-Cough VAS
and a Fatigue-VAS (Table 1).
Digital Collaboration Platform
At study enrolment, each patient will receive a
handheld spirometer, an accelerometer, a tablet
computer and user manuals. Patients will be
able to view their spirometry and accelerometry
data on their tablet computers, which will also
act as a conduit for real-time data transmission
to the collaboration platform, where
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investigators will be able to access their
patients’ data (Fig. 2). In the event that patients
do not wish to have access to their clinical data,
or become distressed as a result of viewing it,
investigators will have the option to block the
patient’s data access on the tablet. Investigators
will be notified via email and text message if a
patient has not measured their pulmonary
function for 3–4 consecutive days or if more
than 10% relative decline from baseline in FVC
(in millilitres) is recorded for three consecutive
days. Patients will also be able to request for
their site investigators to contact them via a
‘‘call back’’ feature on their tablet computer.
Investigators from community sites will be able
to share data (such as high-resolution computed
tomography images and home assessment
results) with other centres via the collaboration
platform, allowing virtual MDT discussions to
take place between community and tertiary
sites (Fig. 2). Discussions between centres can
take place at any time during the study, with all
diagnoses at the discretion of the investigators.
Participation in the virtual MDT is optional,
and the clinical experts included will depend on
the requirements of the individual sites. The
study sponsor will not have access to the digital
collaboration platform. Patient data from the
tablet computers will be anonymised and
transferred to the study database for analysis.
Planned Outcomes
The primary endpoint of this study is the time-
adjusted semi-annual change in FVC (in millil-
itres) in patients with IPF, measured using daily
home spirometry, during the peri-diagnostic
period. A full list of study endpoints is presented
in Table S2 in the Electronic Supplementary
Material.
Secondary endpoints include changes in FVC
in patients with ILD, excluding patients with
IPF, measured using daily home spirometry;
changes in FVC in patients with ILD and IPF,
measured using site spirometry; changes in
physical functional capacity in patients with
ILD and IPF, measured using daily home
accelerometry and site 6MWT; and the correla-
tion between home and site measurements for
pulmonary function and physical functional
capacity. Changes in health status and quality
of life, measured using PROs, and the incidence
of non-elective hospitalisations, investigator-
reported acute exacerbations and mortality will
also be recorded (see Table S2 in the Electronic
Supplementary Material).
Table 1 Outcome measures
Home assessments Site assessments
Daily FVC will be assessed at home FVC will be assessed using site spirometry
Daily physical functional capacity will be assessed using home
accelerometry (steps per day and calorie expenditure)
Physical functional capacity will be assessed at
site visits using the 6MWT
PRO assessments will be completed by patients at the request of the investigator just prior to, or during, site visits
K-BILD questionnaire (short and easy health-status measure in ILD)
mMRC Dyspnoea Scale (dyspnoea)
EQ-5D-5L questionnaire (general well-being)
FAS (fatigue)
VAS (cough/urge to cough/fatigue)
Refer to Table S2 in the Electronic Supplementary Material for further information on all outcomes
6MWT 6-min walk test, EQ-5D-5L 5-Level EuroQol 5-Dimension, FAS Fatigue Assessment Scale, FVC forced vital
capacity, ILD interstitial lung disease, K-BILD King’s Brief Interstitial Lung Disease, mMRC modiﬁed Medical Research
Council, PRO patient-reported outcome, VAS Visual Analogue Scale
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A number of exploratory endpoints will also
be assessed, including an analysis of baseline
characteristics and changes in FVC by ILD sub-
group. At the end of the study, patients and
investigators will complete structured surveys
that will collect data on the usefulness and
practicality of the collaboration platform and
the digital ecosystem; for example, their general
experiences with the technology and whether
investigators collaborated with a tertiary site.
Any non-compliance to home assessments (for
seven or more consecutive days) will be counted
objectively throughout the study period.
This study has no investigational medicinal
product and patients will leave the study prior
to initiating pharmacological treatment for ILD;
therefore, there will be no safety objectives. Any
events thought to be related to a medicinal
product used during the course of a patient’s
standard medical treatment will be reported to
the market authorisation holder or local health
authority, according to local regulatory
requirements.
Data Analysis
The planned sample size of 180 patients is based
on an assumption that approximately 40% of
enrolled patientswill be diagnosedwith IPF, 50%
will be diagnosed with non-IPF ILD and 10%will
receive a non-ILD diagnosis or will remain
undiagnosed 12 months post-enrolment.
The primary endpoint of time-adjusted semi-
annual change in FVC (in millilitres) in patients
with IPF will be presented descriptively, with
two-sided 95% confidence intervals. FVC
change for individual patients will be estimated
by applying a linear regression model to all data
points. The estimated FVC change for each
individual patient will then be used to calculate
the mean FVC change in the overall cohort of
patients with IPF. A repeated-measures mixed
model will be applied to estimate the FVC
change over 6 months as a sensitivity analysis.
The secondary endpoint of time-adjusted
semi-annual change in FVC (in millilitres) in
patients with ILD, excluding patients with IPF,
measured using home spirometry, will be anal-
ysed using the same method as for the primary
endpoint. Changes in physical functional
capacity and PROs will be summarised descrip-
tively over time. The correlation between home
and site measurements of FVC and physical
functional capacity will be analysed using
Pearson’s correlation coefficient, taking the
individual mean FVC changes and accelerome-
try values for each patient into account.
Data Monitoring Committee and Interim
Analyses
The study will be conducted under the leader-
ship of a steering committee. In the absence of
the use of any investigational medicinal pro-
duct, an independent review committee or a
data safety monitoring board/data monitoring
committee will not be needed. Interim analyses
will be performed at least once per year. The
first interim analysis is planned for when 20
enrolled patients are diagnosed with IPF and
can be fully evaluated with regard to the pre-
diagnostic period.
Ethics and Dissemination
This study will be conducted in full confor-
mance with the International Conference on
Harmonisation (ICH) E6 guideline for Good
Clinical Practice and the principles of the Dec-
laration of Helsinki, or the laws and regulations
of the country where the research is conducted,
whichever affords the greater protection to the
individual. The study will comply with the
requirements of the ICH E2A guideline (Clinical
Safety Data Management: Definitions and
Standards for Expedited Reporting).
DISCUSSION
To our knowledge, this will be the first study to
assess disease behaviour during the peri-diag-
nostic period in patients with ILD, including
IPF. Whereas the majority of clinical trials have
collected data from patients after they have
received a confirmed diagnosis of ILD and ini-
tiated pharmacological treatment, this study
has been designed to collect meaningful clinical
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data on the natural history of ILDs at the start of
the diagnostic process. Furthermore, ILD clini-
cal trials have typically investigated longitudi-
nal outcomes, collecting data every
3–6 months. To investigate and identify disease
progression during the immediate pre- and
post-diagnostic periods, there is a clear need for
study designs that allow more frequent data
collection. As such, in addition to the site
assessments, this study will utilise daily home
spirometry and accelerometry to assess short-
term changes in pulmonary function and
physical functional capacity during the peri-di-
agnostic period in patients with ILD.
Previous observational studies utilising home
spirometryhave shown thathomemeasurements
have excellent correlationwith hospital-obtained
readings [26] and are feasible to perform for the
majority of patients [24–26, 28]. Furthermore, the
rate of FVC decline measured using handheld
spirometry has been associated with mortality.
For example, in a cohort of 50 patients with IPF,
the rate of change in FVC assessed at 3 months,
6 months and 12 months was predictive of sub-
sequent mortality [26]. Few studies have also
assessed physical activity using accelerometry in
patients with ILD [22, 23] with the available evi-
dence suggesting that physical activity predicts
mortality in patients with IPF [23].
The daily pulmonary function and physical
activity data collected in this study will help to
address a number of key unmet needs that have
been identified by patients with ILD and clini-
cians involved in their care. First, there is a lack
of data characterising the early course of ILDs,
including IPF. It has been suggested that
detailed information on ILD disease behaviour
is required to establish a working diagnosis and
decide on further patient management, with a
recent Fleischner Society White Paper recom-
mending that disease behaviour should be
considered during multidisciplinary diagnosis
[27]. The data collected in this study will
increase our knowledge of disease behaviour
during the peri-diagnostic period in patients
with ILD, and it is hoped that this knowledge
will help clinicians to form working diagnoses
and reassess patients when disease behaviour is
discordant to the previously established diag-
nosis [27].
Second, many patients with ILD report a
need for improved access to diagnosis and
treatment [15, 16, 29]. For example, in a quali-
tative survey of patients with IPF, the majority
of respondents reported waiting over
12 months for a diagnosis [15]. Similarly, other
surveys of patients with ILD and their caregivers
reported delays of at least 12 months between
symptom onset and a final diagnosis [13, 30]. In
particular, delays can be introduced in the time
period between symptom onset and referral to a
tertiary centre [14, 16]. The reasons for delayed
referral to an ILD specialist identified in previ-
ous studies included initial misdiagnosis with
another condition and geographical barriers to
accessing an MDT [13, 16, 31]. In this study, the
digital collaboration platform will allow com-
munity and tertiary sites to communicate with
each other via virtual MDT discussions, with
community centres able to share clinical data
with tertiary centres for a second opinion on
diagnosis. This design feature has the potential
to empower community centres to deliver
improved care for patients with ILD, thereby
reducing misdiagnoses and unnecessary delays
associated with restricted access to tertiary
centres. While the lack of a control group in our
study will preclude any definite conclusions
regarding the benefit of the digital collaboration
platform on diagnostic delays, the existing lit-
erature base describing diagnostic delays in ILD
will provide a context within which we will be
able to critically evaluate the diagnostic pro-
cesses observed in our study [13–15, 30]. Fur-
thermore, this platform will reduce the need for
patients to travel to tertiary centres to access
specialist diagnostic services and input. In geo-
graphical areas where access to specialist centres
is limited, our study has the potential to sig-
nificantly reduce the inconvenience experi-
enced by patients with ILD and increase patient
satisfaction with their access to specialist care
without having to travel.
A third key unmet need, which has been
highlighted in the European IPF Patient Charter
and the Irish National Patient Charter for IPF, is
the need to provide patients with more infor-
mation regarding their disease, the available
treatments and support services [16, 32]. The
digital collaboration platform used in this study
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will facilitate two-way communication between
patients and clinicians. For example, clinicians
will be alerted automatically to deterioration in
their patients’ FVC andwill be able to contact the
patient, while the ‘‘call back’’ feature on patients’
tablet computers will also enable patients to
request contact from their clinician. This ‘‘call
back’’ feature may also help patients to feel more
comfortable asking questions and could help
them to becomemore familiar with their clinical
data. Empowering patients through access to
their real-time clinical data could provide
patients with further insights into their disease
andmay also helpwith adherence to the study. It
is also possible that the availability of real-time
daily clinical data may also have future applica-
tions; for example, similar to technology used in
chronic obstructive pulmonary disease [33, 34],
the platform could become a useful tool for
predicting acute exacerbations, prompting
patients to seek a consultation on the basis of
patterns in their clinical data.
This study has some novel design aspects,
including minimal inclusion and exclusion cri-
teria, the assessment of disease behaviour pre-
diagnosis, the use of home-based assessments,
few mandatory assessments and site visits, and
the virtual MDT. An additional novel aspect of
this study will include the assessment of mul-
tiple, simple PROmeasures in patients with ILD.
Of particular interest, this study will assess
fatigue, which is among the most common and
limiting symptoms for patients with ILD
[35–37], but to our knowledge is yet to be
assessed in a clinical trial. The subjective expe-
riences of patients with ILD are important
because the individual patient’s perception of
how they feel and function, and how the dis-
ease impacts their life, is not only central to the
patient’s well-being but can also influence
treatment success [38]. Furthermore, PRO mea-
sures can help to facilitate communication
between patients and clinicians, detect
unrecognised problems, guide treatment choi-
ces and monitor treatment response [38].
However, despite the importance of these data,
there is very little knowledge in this area from
clinical trials. The PRO measures that will be
assessed in this study are short, easy to complete
and cover a number of the important aspects of
living with ILD, including dyspnoea, psycho-
logical symptoms, mobility, pain, discomfort,
cough and fatigue. The combination of clinical
data and PROs assessed will ensure that this
study provides meaningful information char-
acterising the multidimensional aspects of ILD
during the peri-diagnostic period.
CONCLUSIONS
To our knowledge, this study will be the first to
characterise disease behaviour in patients with
ILD, including IPF, during the peri-diagnostic
period using real-time, home-based assess-
ments. This study aims to address a number of
key unmet needs experienced by patients with
ILD and the healthcare professionals involved
in their care. In particular, it is hoped that this
study will help to facilitate the early and accu-
rate diagnosis of ILDs by increasing knowledge
about disease behaviour, increasing communi-
cation between community and tertiary centres
and improving communication between clini-
cians and patients. In the future, the virtual
MDT platform used in this study could be used
in clinical practice to facilitate collaboration
between community and tertiary centres, while
reducing inconvenience and delays in diag-
noses for patients.
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